Preoperative levosimendan in heart failure patients undergoing noncardiac surgery

Netherlands Journal of Medicine

Volumn 66, Issue 4, 2008, Pages 154-159

  Katsaragakis, S ^a   Kapralou, A ^a   Markogiannakis, H ^a   Kofinas, G ^a   Theodoraki, E M ^a   Larentzakis, A ^a   Menenakos, E ^a   Theodorou, D ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

Elective noncardiac surgery; Heart failure; Inotropes; Left ventricular function; Perioperative optimisation; Prophylactic preoperative levosimendan infusion

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEVOSIMENDAN; LOOP DIURETIC AGENT; NITRATE; SPIRONOLACTONE;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; AORTA PRESSURE; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ELECTIVE SURGERY; FEMALE; HEART ARRHYTHMIA; HEART CONTRACTION; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE EJECTION TIME; HEART LEFT VENTRICLE FUNCTION; HEART PREEJECTION PERIOD; HEMODYNAMIC MONITORING; HUMAN; HYPOTENSION; INTRAOPERATIVE PERIOD; LOADING DRUG DOSE; MALE; PREOPERATIVE CARE; SURGICAL TECHNIQUE; TRANSTHORACIC ECHOCARDIOGRAPHY;

AGED; AGED, 80 AND OVER; CARDIOTONIC AGENTS; FEMALE; HEART FAILURE; HUMANS; HYDRAZONES; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PREOPERATIVE CARE; PROSPECTIVE STUDIES; PYRIDAZINES; RISK ASSESSMENT; SURGICAL PROCEDURES, ELECTIVE;

EID: 42649121655     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Toller WG, Metzler H. Acute perioperative heart failure. Curr Opin Anaesthesiol 2005;18:129-35.
2. Hernandez AF, Whellan DJ, Stroud S, Sun JL, O'Connor CM, Jollis JG. Outcomes in heart failure patients after major noncardiac surgery. J Am Coll Cardiol 2004;44:1446-53.
3. Flancbaum L, Ziegler DW, Choban PS. Preoperative intensive care unit admission and hemodynamic monitoring in patients scheduled for major elective noncardiac surgery: a retrospective review of 95 patients. J Cardiothorac Vasc Anesth 1998;12:3-9.
4. Hayes MA, Timmins AC, Yau EH, Palazzo M, Hinds CJ, Watson D. Elevation of systemic oxygen delivery in the treatment of critically ill patients. N Engl J Med 1994;330:1717-22.
5. Follath F, Cleland JG, Just H, et al; Steering Committee and Investigators of the Levosimendan Infusion versus Dobutamine (LIDO) Study. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002;360:196-202.
6. Moiseyev VS, Põder P, Andrejevs N, et al; RUSSLAN Study Investigators. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur, Heart J 2002;23:1422-32.
7. Ng TM. Levosimendan, a new calcium-sensitizing inotrope for heart failure. Pharmacotherapy 2004;24:1366-84.
8. McLean AS, Huang SJ, Nalos M, Ting I. Duration of the beneficial effects of levosimendan in clecompensated heart failure as measured by echocardiographic indices and B-type natriuretic pepticle. J Cardiovasc Pharmacol 2005;46:830-5.
9. Malliotakis P, Xenikakis T, Linardakis M, Hassoulas J. Haemodynamic effects of levosimendan for low cardiac output after cardiac surgery: a case series. Hellenic J Cardiol 2007;48:80-8.
10. Siirilä-Waris K, Suojaranta-Ylinen R, Harjola Levosimendan in cardiac surgery. J Cardiothorac Vasc Anesth 2005;19:345-9.
11. Nijhawan N, Nicolosi AC, Montgomery MW, Aggarwal A, Pagel PS, Warltier DC. Levosimendan enhances cardiac performance after cardiopulmonary bypass: a prospective, randomized placebo-controlled trial. J Cardiovasc Pharmacol 1999;34:219-28.
12. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646-9.
13. Goldman L, Caldera DL, Nussbaum SR, et al. Multifactorial index of cardiac risk in noncardiac surgical procedures. N Engl J Med 1977;297:845-50.
14. The criteria committee of the New York Heart Association. Nomenclature and Criteria for diagnosis. 9th ed. Boston: Little Brown, 1994.
15. American Society of Anesthesiologists, New classification of physical status. Anesthesiology 1963;24:111.
16. Toufektzian L, Theodorou D, Larentzakis A, Misthos P, Katsaragakis S. Optimization of cardiac performance in chronic heart failure patients undergoing elective non-cardiac surgery. Curr Anaesth Crit Care 2007;18:50-7.
17. Avgeropoulou C, Andreadou I, Markantonis-Kyroudis S, et al. The Ca2+-sensitizer levosimendan improves oxidative damage, BNP and pro-inflammatory cytokine levels in patients with advanced decompensated heart failure in comparison to dobutamine. Eur J Heart Fail 2005;7:882-7.
18. Adamopoulos S, Parissis JT, Illiodromitis EK, et al. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. Am J Cardiol 2006;98:102-6.
19. Trikas A, Antoniades C, Latsios G, et al. Long-term effects of levosimendan infusion on inflammatory processes and sFas in patients with severe heart failure. Eur J Heart Fail 2006;8:804-9.
20. Mavrogeni S, Giamouzis G, Papadopoulou E, et al. A 6-month follow-up of intermittent levosimendan administration effect on systolic function, specific activity questionnaire, and arrhythmia in advanced heart failure. J Card Fail 2007;13:556-9.
21. Slawsky MT, Colucci WS, Gottlieb SS, et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators. Circulation 2000;102:2222-7.
22. Cohn JN, Rector TS. Prognosis of congestive heart failure and predictors of mortality. Am J Cardiol 1988;62:A25-30.
23. Gradman A, Deedwania P, Cody R, et al. Predictors of total mortality and sudden death in mild to moderate heart failure. Captopril-Digoxin Study Group. J Am Coll Cardiol 1989;14:564-70; discussion 571-2.
24. Haikala H, Kaivola J, Nissinen E, Wall P, Levijoki J, Lindén IB. Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan. J Mol Cell Cardiol 1995;27:1859-66.
25. Kivikko M, Lehtonen L. Levosimendan: a new inodilatory drug for the treatment of clecompensated heart failure. Curr Pharm Des 2005;11:435-55.